Search clinical trials for: CervarixTM (GSK580299)

Total 77 results

GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Infections, Papillomavirus

United States, Canada
GlaxoSmithKline

Completed

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

United States, Canada
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand

Infections, Papillomavirus

Taiwan, Thailand, Brazil
GlaxoSmithKline

Completed

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

Russian Federation, Singapore, Australia, Portugal
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Infections, Papillomavirus

Netherlands, Sweden
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Infections, Papillomavirus

Romania, Italy, Slovakia
GlaxoSmithKline

Completed

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Infections, Papillomavirus

Canada, United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Human Papillomavirus (HPV) Infection

Senegal, Tanzania
GlaxoSmithKline

Completed

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Infections, Papillomavirus | Papillomavirus Vaccines

United States
GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium, United States
National Institute for Public Health and the Environment...

Terminated

Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination (TANGO)

Human Papillomavirus Infection
GlaxoSmithKline

Completed

Drug Use Investigation for Cervarix®

Infections, Papillomavirus
GlaxoSmithKline

Completed

Cervarix Long-term Safety Surveillance (PGRx)

Infections, Papillomavirus
Henry M. Jackson Foundation for the Advancement...
Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... and other collaborators

Active, not recruiting

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (HVRRICANE)

HIV Infections

South Africa
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

Infections, Papillomavirus

Germany, Poland
GlaxoSmithKline

Completed

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Infections, Papillomavirus | Papillomavirus Vaccines

Denmark, Poland, Lithuania
GlaxoSmithKline

Completed

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

Infections, Papillomavirus
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Infections, Papillomavirus

Hong Kong
Public Health England

Completed

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls (HPV CSP01)

HPV Infections

United Kingdom
GlaxoSmithKline
Clinical Practice Research Datalink

Completed

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

Infections, Papillomavirus

United Kingdom
GlaxoSmithKline

Completed

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

Cervical Intraepithelial Neoplasia | Papillomavirus Type 16/18 Infection

Estonia
Murdoch Childrens Research Institute
Department of Foregin Affairs and Trade, Australia; Ministry of Health, Fiji; The Royal Women Hospital and other collaborators

Completed

Evaluation of Long Term Immunity Following HPV Vaccination

Cervical Cancer | Anogenital Warts

Fiji
N.M. Wulffraat
National Institute for Public Health and the Environment (RIVM)

Completed

Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease (HPV-kind)

Systemic Lupus Erythematosus | Juvenile Idiopathic Arthritis | Juvenile Dermatomyositis

Netherlands
GlaxoSmithKline

Completed

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Infections, Papillomavirus

Finland
GlaxoSmithKline

Completed

Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

Infections, Papillomavirus

Korea, Republic of
GlaxoSmithKline

Withdrawn

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Infections, Papillomavirus
GlaxoSmithKline

Withdrawn

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Infections, Papillomavirus
Cancer Prevention and Research Institute, Italy
University of Florence; Istituto Toscano Tumori

Completed

Effect of HPV Vaccination on Women Aged 25 Years

Cervical Cancer

Italy
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Infections, Papillomavirus

South Africa
Instituto Nacional de Salud Publica, Mexico

Completed

FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program (FASTER)

Cervical Intraepithelial Neoplasia | HPV-Related Cervical Carcinoma

Mexico
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Infections, Papillomavirus | Papillomavirus Vaccines

United States, Russian Federation, Canada, Singapore, Netherlands, United Kingdom, Thailand, Australia, Philippines, Mexico, Portugal, Peru
CHU de Reims

Completed

Comparing Health Services Interventions for the Prevention of HPV-related Cancer (CoheaHr-WP4)

Cervical Cancer

France
GlaxoSmithKline

Withdrawn

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Human Papillomavirus Infection
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Panama, Mexico, Colombia
International Vaccine Institute
Ministry of Health, Thailand

Enrolling by invitation

Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand (IVIHPV1)

Healthy

Thailand
GlaxoSmithKline

Completed

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Infections, Papillomavirus

Germany, Taiwan, Thailand, Canada, Italy
GlaxoSmithKline

Completed

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Infections, Papillomavirus

United States, Canada, Singapore, Netherlands, United Kingdom, Russian Federation, Portugal
GlaxoSmithKline

Completed

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Infections, Papillomavirus

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Infections, Papillomavirus

Singapore, Hong Kong, France, Sweden
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Cervical Intraepithelial Neoplasia | Papillomavirus Infection

Taiwan, Germany, Colombia, Honduras, Panama
Instituto Nacional de Salud Publica, Mexico
Secretaria de Salud, Mexico

Completed

Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

Healthy

Mexico
London School of Hygiene and Tropical Medicine
National Cancer Institute (NCI); Karolinska Institutet; Institut Català d'Oncologia and other collaborators

Active, not recruiting

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS)

Human Papilloma Virus

Tanzania
University of Aarhus
Aarhus University Hospital

Completed

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults (HIPAVAC)

HIV | Human Papillomavirus

Denmark
GlaxoSmithKline

Terminated

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Human Papillomavirus Infection Leading to Cervical Cancer

Philippines

3

Subscribe